JSR Life Sciences: John Gabrielson Explains Impact of Clinical Efficacy Tests, Government Policies on Biosimilar Development
John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, shares his perspective on how clinical efficacy testing and recent actions from the Biden Administration, such as the executive order on biotechnology investment, impact biosimilar development.
Read full article »
JSR is a life sciences company that engages in the research and development of chromatography resin, research reagents and biopharmaceutical products.
Read more